Safety of TEG001 in patients with r/r AML, high-risk MDS or MM
Recruiting
- Conditions
- Acute Myeolid Leukemia (AML)<br />Myelodysplastic syndromes (MDS)<br />Multiple Myeloma (MM)<br /><br />Acute Myeloïde Leukemie (AML)<br />Myelodysplastisch syndroom (MDS)<br />Multipel Myeloom (MM)<br />Ziekte van Kahler
- Registration Number
- NL-OMON25189
- Lead Sponsor
- niversity Medical Center Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 18
Inclusion Criteria
Age ¡Ý 18-years
- Relapsed/refractory Acute Myeloid Leukemia, high-risk Myelodysplastic Syndrome (IPSS-R score >4,5) or Multiple Myeloma, for which no remaining standard of care or approved treatment options are available
Exclusion Criteria
- In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures
- Central Nervous System involvement of the haematological malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number of patient with one or more Dose Limiting Toxicities
- Secondary Outcome Measures
Name Time Method 1. number of Adverse Events<br /><br>2. description of clinical responses<br /><br>3. levels of TEG001 in peripheral blood